Advertisement

Role of MMP2 in Brain Metastasis

  • George Stoica
  • Gina Lungu
Chapter
Part of the Tumors of the Central Nervous System book series (TCNS, volume 13)

Abstract

Matrix metalloproteinase 2 (MMP2) is important in breast cancer (BC) invasion and metastasis.

In order to study the expression of MMP2, in breast cancer brain metastasis, we used a syngeneic rat model of distant metastasis of ENU1564, a carcinogen-induced mammary adenocarcinoma cell line. At 6 weeks post left-ventricle inoculation we observed development of micro-metastasis in the brain. Immunohistochemistry (IHC) and Western blotting (WB) analyses showed that MMP2 protein expressions were significantly higher in neoplastic brain tissue compared to normal brain tissue. These results were confirmed by RT-PCR and gelatin zymography increased in MMP2 and activity in brain metastasis. The MMP2 mechanism of action in the brain is still under intense scrutiny. To study the role of MMP2 in the development of BC brain metastasis we transfected ENU1564 rat mammary adenocarcinoma cells with tissue inhibitor of MMP2 (TIMP2). Animals inoculated with ENU1564-TIMP2 cells had decreased orthotopic tumor growth, decreased orthotopic metastastic behavior and did not develop brain metastases. Mitogen activated protein kinase (MAPK) pathway components, such as ERK1/2, have been correlated to MMP expression and/or astrocyte activity. We found that BC brain metastases have peripheral astrocyte reactivity and higher expression of glial fibrillary acidic protein (GFAP) and phosphorylated-ERK1/2 (p-ERK1/2). Blockage of ERK1/2 phosphorylation by treatment with MEK inhibitor (PD98059) decreased the expression of MMP2 in cancer cells grown in rat astrocyte-conditioned media. Our results are highly suggestive that MMP2 plays a role in the development of BC metastases, in particular to the brain. Furthermore, our results suggest that astrocyte factors and the ERK1/2 signaling pathway may be associated with BC brain metastasis development; and that ERK1/2 may regulate MMP2 in a way that is modifiable by astrocyte factors.

Keywords

Breast Cancer Brain Metastasis Glial Fibrillary Acidic Protein MMP2 Expression Mitogen Activate Protein Kinase Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alessandrini A (2002) The roles of map kinases in controlling cancer metastasis. In: Welch DR (ed) Cancer metastasis-related genes, V. 3, vol 20. Kluwer Academic, Boston, pp 35–51CrossRefGoogle Scholar
  2. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P (1999) Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 47:1575–1580PubMedCrossRefGoogle Scholar
  3. Danilewicz M, Sikorska B, Wagrowska-Danilewicz M (2003) Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer. Med Sci Monit 9:MT42–MT47PubMedGoogle Scholar
  4. Dzwonek J, Rylski M, Kaczmarek L (2004) Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 567:129–135PubMedCrossRefGoogle Scholar
  5. Fujimake T, Price JE, Fan D, Bucana CD, Itoh K, Kirino T, Fidler IJ (1996) Selective growth of human melanoma cells in the brain parenchyma of nude mice. Melanoma Res 6:363–371CrossRefGoogle Scholar
  6. Gakiopoulou H, Nakopoulou L, Siatelis A (2003) Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 9:5573–5581PubMedGoogle Scholar
  7. Hall DG, Stoica G (1994) Characterization of brain and bone-metastasizing clones selected from an ethylnitrosurea-induced rat mammary carcinoma. Clin Exp Metastasis 12:283–295PubMedCrossRefGoogle Scholar
  8. Hanemaaijer R, Verheijen JH, Maguire TM (2000) Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 86:204–207PubMedCrossRefGoogle Scholar
  9. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149:273–282PubMedCentralPubMedGoogle Scholar
  10. Hynes RO (2003) Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113:821–823PubMedCrossRefGoogle Scholar
  11. Jones JL, Glynn P, Walker RA (1999) Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189:161–168PubMedCrossRefGoogle Scholar
  12. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 88:1318–1326Google Scholar
  13. Lafleur MA, Tester AM, Thompson EW (2003) Selective involvement of TIMP-2 in the second activational cleavage of pro-MMP-2: refinement of the pro-MMP-2 activation mechanism. FEBS Lett 553:457–463PubMedCrossRefGoogle Scholar
  14. Le DM, Besson A, Fogg DK (2003) Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 23:4034–4043PubMedGoogle Scholar
  15. Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Lohrs U (1999) Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res 19:4257–4264PubMedGoogle Scholar
  16. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, Cheong JH, Ryu JH, Ko KH (2003) Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide- stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41:15–24PubMedCrossRefGoogle Scholar
  17. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2004) A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10:1057–1063PubMedCrossRefGoogle Scholar
  18. Leveque T, Le Pavec G, Boutet A (2004) Differential regulation of gelatinase A and B and TIMP-1 and -2 by TNFalpha and HIV virions in astrocytes. Microbes Infect 6:157–163PubMedCrossRefGoogle Scholar
  19. Li H, Lindenmeyer F, Grenet C (2001) AdTIMP-2 inhibits tumor growth, angiogenesis, and metastases, and prolongs survival in mice. Hum Gene Ther 5:515–526CrossRefGoogle Scholar
  20. Liuzzi GM, Mastroianni CM, Latronico T (2004) Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127:398–407PubMedCrossRefGoogle Scholar
  21. Massengale JL, Gasche Y, Chan PH (2002) Carbohydrate source influences gelatinase production by mouse astrocytes in vitro. Glia 38:240–245PubMedCrossRefGoogle Scholar
  22. Mendes O, Kim HT, Stoica G (2005) Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 22:237–246PubMedCrossRefGoogle Scholar
  23. Muir EM, Adcock KH, Morgenstern DA (2002) Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 100:103–117PubMedCrossRefGoogle Scholar
  24. Nagashima G, Suzuki R, Asai J (2002) Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg 104:125–131PubMedCrossRefGoogle Scholar
  25. Nie J, Pei D (2003) Direct activation of pro-matrix metalloproteinase-2 by leukolysin/membrane-type 6 matrix metalloproteinase/matrix metalloproteinase 25 at the asn(109)-Tyr bond. Cancer Res 63:6758–6762PubMedGoogle Scholar
  26. Nishizuka I, Ishikawa T (2002) Analysis of gene expression involved in brain metastases from breast cancer using cDNA microarray. Breast Cancer 9:26–32PubMedCrossRefGoogle Scholar
  27. Ohshiba T, Miyaura C, Inada M, Ito A (2003) Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Cancer 90:1414–1421Google Scholar
  28. Pan MR, Hung WC (2002) Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 277:32775–32780PubMedCrossRefGoogle Scholar
  29. Remacle A, McCarthy K, Noel A (2000) High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 89:118–121PubMedCrossRefGoogle Scholar
  30. Scott KA, Holdsworth H, Balkwill FR, Dias S (2000) Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment 133 in a murine breast cancer model. Br J Cancer 83:1538–1543PubMedCentralPubMedCrossRefGoogle Scholar
  31. Sierra A, Price JE, Garcia-Ramirez M (1997) Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest 77:357–368PubMedGoogle Scholar
  32. Somerville RP, Oblander SA, Apte SS (2003) Matrix metalloproteinases: old dogs with new tricks. Genome Biol 4:205–216CrossRefGoogle Scholar
  33. Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573PubMedCrossRefGoogle Scholar
  34. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89:1270–1275PubMedCentralPubMedCrossRefGoogle Scholar
  35. Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, Kern FG, Stetler- Stevenson WG, Lippman ME, Thompson EW (2004) Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 64:652–658PubMedCrossRefGoogle Scholar
  36. Yoneda T (2000) Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 5:75–81PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Veterinary PathobiologyTexas A&M UniversityCollege StationUSA

Personalised recommendations